Tradewinds Capital Management LLC held its stake in Eli Lilly and Company (NYSE:LLY) during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,345 shares of the company’s stock at the end of the second quarter. Tradewinds Capital Management LLC’s holdings in Eli Lilly and were worth $111,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Joel Isaacson & Co. LLC boosted its stake in shares of Eli Lilly and by 1.5% in the 1st quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock worth $283,000 after buying an additional 50 shares during the last quarter. Sumitomo Life Insurance Co. boosted its stake in shares of Eli Lilly and by 4.4% in the 2nd quarter. Sumitomo Life Insurance Co. now owns 32,507 shares of the company’s stock worth $2,675,000 after buying an additional 1,370 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Eli Lilly and by 7.8% in the 2nd quarter. Russell Investments Group Ltd. now owns 671,327 shares of the company’s stock worth $55,258,000 after buying an additional 48,706 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Eli Lilly and by 93.6% in the 1st quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock worth $250,681,000 after buying an additional 1,441,200 shares during the last quarter. Finally, Stephens Inc. AR boosted its stake in shares of Eli Lilly and by 4.5% in the 1st quarter. Stephens Inc. AR now owns 44,023 shares of the company’s stock worth $3,703,000 after buying an additional 1,901 shares during the last quarter. Hedge funds and other institutional investors own 75.72% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Tradewinds Capital Management LLC Maintains Position in Eli Lilly and Company (LLY)” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.watchlistnews.com/tradewinds-capital-management-llc-maintains-position-in-eli-lilly-and-company-lly/1609078.html.

A number of brokerages have recently weighed in on LLY. Berenberg Bank restated a “buy” rating and issued a $98.00 target price on shares of Eli Lilly and in a research note on Friday, August 4th. Cowen and Company reiterated a “buy” rating and issued a $95.00 price objective on shares of Eli Lilly and in a research note on Wednesday. Oppenheimer Holdings, Inc. downgraded Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price objective on the stock. in a research note on Wednesday, July 26th. BMO Capital Markets reiterated an “underperform” rating and issued a $73.00 price objective on shares of Eli Lilly and in a research note on Wednesday, July 26th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $89.00 price objective on shares of Eli Lilly and in a research note on Thursday, August 31st. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company. Eli Lilly and presently has an average rating of “Hold” and an average target price of $88.27.

Eli Lilly and Company (NYSE:LLY) opened at 86.96 on Thursday. The company has a market cap of $91.74 billion, a PE ratio of 37.63 and a beta of 0.34. The stock has a 50 day moving average of $81.75 and a 200 day moving average of $82.08. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $87.16.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company’s revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.86 EPS. Equities analysts expect that Eli Lilly and Company will post $4.16 earnings per share for the current year.

In other news, major shareholder Lilly Endowment Inc sold 220,000 shares of Eli Lilly and stock in a transaction on Monday, July 31st. The shares were sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the transaction, the insider now owns 124,049,283 shares in the company, valued at approximately $10,307,254,924.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 785,000 shares of company stock worth $65,153,600 in the last quarter. Corporate insiders own 0.20% of the company’s stock.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.